Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
But most often, the best results come two months afterward
The combination of cinnamon's insulin sensitivity effects and GLP-1 medications can potentially cause blood sugar to drop too low
10.1080/13543784.2021.1868433 188 RobsonR.KundurA
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Succinate is an inflammatory signal that induces IL-1 through HIF-1
A faint yellow tint can occur, but dark yellow or brown discoloration may indicate degradation
